药品详细
Suprofen(舒洛芬)
化学结构式图
中文名
舒洛芬
英文名
Suprofen
分子式
C14H12O3S
化学名
2-{4-[(thiophen-2-yl)carbonyl]phenyl}propanoic acid
分子量
Average: 260.308
Monoisotopic: 260.05071494
Monoisotopic: 260.05071494
CAS号
40828-46-4
ATC分类
M01A 未知
药物类型
small molecule
阶段
approved
商品名
Maldocil;Masterfen;Profenal;Srendam;Sulproltin;Suprocil;Suprol;Sutoprofen;Topalgic;
同义名
Suprofene [INN-French];Suprofenum [INN-Latin];
基本介绍
An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. [PubChem]
生产厂家
- Alcon laboratories inc
封装厂家
参考
Synthesis Reference | Not Available |
General Reference | Not Available |
剂型
规格
化合物类型
Type | small molecule |
Classes |
|
Substructures |
|
适应症
ANTIINFLAMMATORY AND ANTIRHEUMATIC 消炎抗风湿;
药理
Indication | Used as eye drops to inhibit the miosis (pupil constriction) that may occur during ocular surgery. | ||||||||||||||||
Pharmacodynamics | Suprofen is a non-steroidal anti-inflammatory analgesic and antipyretic. Ophthalmic anti-inflammatory medicines are used in the eye to lessen problems that can occur during or after some kinds of eye surgery. Sometimes, the pupil of the eye gets smaller during an operation (pupil constriction), making it more difficult for the surgeon to reach some areas of the eye. Suprofen is used to help prevent this. | ||||||||||||||||
Mechanism of action | Suprofen binds to the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes, preventing the synthesis of prostaglandins and reducing the inflammatory response. Cyclooxygenase catalyses the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation. The overall result is a reduction in pain and inflammation in the eyes and the prevention of pupil constriction during surgery. Normally trauma to the anterior segment of the eye (especially the iris) increases endogenous prostaglandin synthesis which leads to constriction of the iris sphincter. | ||||||||||||||||
Absorption | Not Available | ||||||||||||||||
Volume of distribution | Not Available | ||||||||||||||||
Protein binding | 20% | ||||||||||||||||
Metabolism |
Primarily hepatic (mainly via cytochrome P450 isozyme 2C9).
Important The metabolism module of DrugBank is currently in beta. Questions or suggestions? Please contact us.
|
||||||||||||||||
Route of elimination | Not Available | ||||||||||||||||
Half life | Not Available | ||||||||||||||||
Clearance | Not Available | ||||||||||||||||
Toxicity | Symptoms of overdose include bleeding in the eye or redness or swelling of the eye or the eyelid, blurred vision or other change in vision, fever or chills, itching or tearing, nausea or vomiting, pain, sensitivity to light, shortness of breath, sticky or matted eyelashes, swelling of face, throbbing pain, tightness in chest, troubled breathing, and wheezing. | ||||||||||||||||
Affected organisms |
|
||||||||||||||||
Pathways |
|
理化性质
Properties | |||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
State | solid | ||||||||||||||||||||||||||||||||||||||||||
Experimental Properties |
|
||||||||||||||||||||||||||||||||||||||||||
Predicted Properties |
|
药物相互作用
食物相互作用
Not Available